News/Tech/Biotech

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development

Monday, February 9, 2026 at 5:57 AM

Biotech Partnership Cancer Treatments Eli Lilly Innovent Biologics

Innovent Biologics has formed a partnership with Eli Lilly to develop treatments for cancer and immune system diseases, with potential milestone payments reaching up to $8.5 billion.

Story Timeline: Trump's Ukraine Peace Talks & Security Guarantee Offers

Feb 7, 2026Big Tech's $700 Billion AI Capital Push by 2026 Reshapes Investment Landscape.

Feb 7, 2026Four Tech Giants Commit $630 Billion to AI by 2026, Matching Historic U.S. Investments

Feb 7, 2026Novo Nordisk Faces Profit Headwinds as GLP-1 Pricing Pressures Intensify

Feb 7, 2026Dow's Historic Climb Above 50,000 Ignites Investor Optimism After Tech Dip

Feb 8, 2026Tech Giants Nvidia, Broadcom Propel Dow Jones Industrial Average Beyond 50,000

Read More On

Innovent Biologics Strikes Partnership Deal With Eli Lillywsj.com

Eli Lilly, Innovent Biologics to Develop New Medicines in Oncology, Immunology Under Collaboration - marketscreener.commarketscreener.com

Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology - Yahoo Finance Singaporesg.finance.yahoo.com

Innovent Biologics partners with Eli Lilly By Investing.com - Investing.com South Africaza.investing.com

Related Articles

Tech★★Similarity: 72% · 23d ago

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

Markets★★Similarity: 64% · 28d ago

AbbVie Revenue Rises on Immunology Growth

AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.

Markets★★Similarity: 61% · 26d ago

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Markets★★Similarity: 61% · 28d ago

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.